We are live on ! Find out more
EC

Elmind Capital Portfolio holdings

AUM $398M
This Fund
S&P 500
This Quarter Est. Return
+20.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$398M
AUM Growth
+$45.8M
Cap. Flow
+$10.9M
Cap. Flow %
2.73%
Top 10 Hldgs %
66.6%
Holding
39
New
5
Increased
9
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$15.4M
2
RLAY icon
Relay Therapeutics
RLAY
+$13.5M
3
SMMT icon
Summit Therapeutics
SMMT
+$8.76M
4
INSM icon
Insmed
INSM
+$7.87M
5
PCVX icon
Vaxcyte
PCVX
+$7.38M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$20.6M
2
CGON icon
CG Oncology
CGON
+$19.7M
3
TYRA icon
Tyra Biosciences
TYRA
+$10.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.34M
5
MBX
MBX Biosciences
MBX
+$4.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.44B
$45.3M 11.38%
1,170,740
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.8B
$40.6M 10.19%
1,855,000
– –
CLDX icon
3
Celldex Therapeutics
CLDX
$3.18B
$36.8M 9.25%
990,000
+125,000
+14% +$4.04M
RLAY icon
4
Relay Therapeutics
RLAY
$4.26B
$27.4M 6.89%
1,465,279
+928,333
+173% +$13.5M
PCVX icon
5
Vaxcyte
PCVX
$9.1B
$26.3M 6.61%
452,340
+135,840
+43% +$7.38M
VERA icon
6
Vera Therapeutics
VERA
$2.49B
$18.7M 4.71%
436,518
-45,982
-10% -$1.71M
PHVS icon
7
Pharvaris
PHVS
$2.6B
$18.2M 4.57%
525,750
+50,000
+11% +$1.51M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.71B
$18.1M 4.55%
984,931
+450,000
+84% +$7.25M
CTMX icon
9
CytomX Therapeutics
CTMX
$745M
$17.1M 4.29%
4,550,000
– –
TVTX icon
10
Travere Therapeutics
TVTX
$6.36B
$16.6M 4.18%
292,600
+115,000
+65% +$5.1M
LEGN icon
11
Legend Biotech
LEGN
$3.99B
$16.5M 4.14%
+570,569
New +$15.4M
BEAM icon
12
Beam Therapeutics
BEAM
$3.15B
$16.3M 4.11%
476,338
– –
CGEM icon
13
Cullinan Oncology
CGEM
$1.45B
$12.6M 3.16%
690,000
+160,000
+30% +$2.38M
NRIX icon
14
Nurix Therapeutics
NRIX
$2.79B
$11.2M 2.8%
460,000
– –
KRYS icon
15
Krystal Biotech
KRYS
$10.6B
$8.18M 2.05%
22,000
– –
UTHR icon
16
United Therapeutics
UTHR
$22.6B
$8.13M 2.04%
15,000
– –
SMMT icon
17
Summit Therapeutics
SMMT
$11.4B
$7.19M 1.81%
+493,820
New +$8.76M
INSM icon
18
Insmed
INSM
$26.5B
$6.93M 1.74%
+65,000
New +$7.87M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.52B
$5.2M 1.31%
520,000
-480,000
-48% -$4.34M
MBX
20
MBX Biosciences
MBX
$3.2B
$5.02M 1.26%
91,000
-120,000
-57% -$4.19M
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.67B
$4.66M 1.17%
38,000
– –
URGN icon
22
UroGen Pharma
URGN
$2.22B
$4.42M 1.11%
120,000
-100,000
-45% -$2.71M
DBVT
23
DBV Technologies
DBVT
$906M
$4.35M 1.09%
265,000
– –
ALMS
24
Alumis Inc
ALMS
$3B
$3.66M 0.92%
130,000
– –
SUPN icon
25
Supernus Pharmaceuticals
SUPN
$2.57B
$3.26M 0.82%
70,000
+50,000
+250% +$2.4M
1
2

Similar funds

FFS
Fischer Financial Services Harrisburg, Pennsylvania $398M AUM 22.91% 1-Year Est. Return
SFS
Stiles Financial Services Edina, Minnesota $398M AUM 55.89% 1-Year Est. Return
SIC
Shoker Investment Counsel Oxford, Ohio $398M AUM 39.01% 1-Year Est. Return
SIAS
Summit Investment Advisory Services Roseville, Minnesota $398M AUM 21.26% 1-Year Est. Return
HVP
Hudson Value Partners Palm Beach, Florida $399M AUM 48.26% 1-Year Est. Return
AC
Alfreton Capital Radlett, Hertfordshire, United Kingdom $399M AUM 20.53% 1-Year Est. Return
W
WorthPointe La Jolla, California $399M AUM 22.49% 1-Year Est. Return
CL
COWA LLC Tulsa, Oklahoma $399M AUM 25.74% 1-Year Est. Return

Elmind Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Elmind Capital held 39 positions worth $398M, up 13% from $352M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Elmind Capital's Q2 2026 filing shows 5 new, 9 increased, 6 reduced and 4 closed positions. Its largest new stake was Legend Biotech: 570,569 shares worth $16.5M. The largest sale was KalVista Pharmaceuticals, an estimated $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Elmind Capital's largest Q2 2026 buy was Legend Biotech: 570,569 shares worth $16.5M.
  • Elmind Capital added most to Relay Therapeutics in Q2 2026, an estimated $13.5M increase.
  • Elmind Capital's biggest Q2 2026 reduction was Tyra Biosciences, cutting an estimated $10.9M.
  • Elmind Capital fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $20.6M.
  • Elmind Capital's ten largest holdings make up 67% of its $398M portfolio in Q2 2026.
  • Elmind Capital opened 5 new positions and closed 4 in Q2 2026.
  • Elmind Capital's portfolio value rose 13% quarter-over-quarter to $398M.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.